Dr Calvin Stiller has been appointed chairman of the board of directors for Aggregate Therapeutics Inc, a spin-off from the Stem Cell Network of Centres of Excellence. Stiller has enjoyed a long and successful career as a professor, researcher, businessman and entrepreneur. Since graduating from the Univ of Saskatchewan in 1970, he has spearheaded the use of cyclosporine as a therapy for transplant rejection at the John P Robarts Research Institute, founded several companies in the areas of seniors' care and venture capital investment and headed the Ontario Research and Development Challenge Fund. In 1999, a research chair in xenotransplantation at the Univ of Western Ontario was named in his honour. He is also board chair of Genome Canada....